2026-07-22T05:26:32Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/227782024-11-28T16:31:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16938col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16968col_20.500.12105_16978col_20.500.12105_16981

00925njm 22002777a 4500 dc Rodriguez-Otero, Paula author Victoria Mateos, Maria author Martinez-Lopez, Joaquin author Hernandez, Miguel T author Ocio, Enrique M author Rosinol, Laura author Martinez, Rafael author Teruel, Ana Isabel author Gutierrez, Norma C author Bargay Lleonart, Joan author Bengoechea, Enrique author Gonzalez, Yolanda author Perez de Oteyza, Jaime author Gironella, Mercedes author Nunez-Cordoba, Jorge M author Encinas, Cristina author Martin, Jesus author Cabrera, Carmen author Palomera, Luis author de Arriba, Felipe author Cedena, Maria Teresa author Puig, Noemi author Oriol, Albert author Paiva, Bruno author Blade, Joan author Lahuerta, Juan Jose author San Miguel, Jesus F author 2019-03-18 Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years. Rodriguez-Otero P, Mateos MV, Martinez-Lopez J, Hernandez MT, Ocio EM, Rosinol L, et al. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer J. 2019 Mar 18;9:36. 10.1038/s41408-019-0176-x 2044-5385 Blood Cancer Journal http://hdl.handle.net/20.500.13003/17583 30886139 L626798367 2-s2.0-85063024454 https://hdl.handle.net/20.500.12105/22778 462349100002 Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature